Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033249 | 1.00 | KDM4E (0.49) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL22346282 | 0.84 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL22346281 | 0.84 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL22346294 | 0.83 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL22346293 | 0.83 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL18274606 | 0.78 | GAA (0.51) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL6648852 | 0.77 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL44233 | 0.75 | POLB (0.55) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL503092 | 0.75 | POLB (0.55) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL44234 | 0.75 | POLB (0.55) | KDM4ESMN1; SMN2ALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334759-B1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2019-09-04 | — | — | EP | claimed |
| EP-3334759-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | Farmagens Health Care Srl (IT) | 2018-06-20 | — | — | EP | claimed |
| WO-2017025846-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2017-02-16 | — | — | WO | claimed |
| US-20030143664-A1 | Products of manufacture and processes for peptide synthesis | DIVERSA CORPORATION (US) | 2003-07-31 | — | — | US | claimed |
| WO-2003048189-A2 | PRODUCTS OF MANUFACTURE AND PROCESSES FOR PEPTIDE SYNTHESIS | DIVERSA CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| US-12617818-B2 | Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them | UNIVERSITY OF NORTH TEXAS (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260116948-A1 | T CELL RECEPTOR CONSTRUCTS AND USES THEREOF | BIONTECH US INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115288-A1 | T CELL MANUFACTURING COMPOSITIONS AND METHODS | BIONTECH US INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20260048116-A1 | PROTEIN ANTIGENS AND USES THEREOF | BIONTECH US INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3365354-B1 | PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT | CANBAS CO LTD (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034223-A1 | BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN | NEW YORK UNIVERSITY (US) | 2026-02-05 | — | — | US | disclosed |
| WO-1995013291-A1 | NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE | NEW YORK UNIVERSITY (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994005695-A9 | POLYPEPTIDES OF G-COUPLED RECEPTOR PROTEINS, AND COMPOSITIONS AND METHODS THEREOF | — | 1994-05-11 | — | — | WO | disclosed |
| WO-1994003601-A9 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | — | 1994-03-31 | — | — | WO | disclosed |
| WO-1994005695-A1 | POLYPEPTIDES OF G-COUPLED RECEPTOR PROTEINS, AND COMPOSITIONS AND METHODS THEREOF | NEW YORK UNIVERSITY (US) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994003601-A2 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | NEW YORK UNIVERSITY (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0377665-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE. | UNIV TEXAS (US) | 1990-07-18 | — | — | EP | disclosed |
| WO-1989009786-A1 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1989-10-19 | — | — | WO | disclosed |
| WO-1989001944-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115288-A1 | T CELL MANUFACTURING COMPOSITIONS AND METHODS | CD14, CD4, IL2RA | KDM4E 4135/4885SMN1; SMN2 1881/4885ALDH1A1 4809/4885 |
| US-20260048116-A1 | PROTEIN ANTIGENS AND USES THEREOF | HLA-DRB1, MICA, TAP2 | KDM4E 2008/4885SMN1; SMN2 3138/4885ALDH1A1 4528/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | KDM4E 2895/4885SMN1; SMN2 2636/4885ALDH1A1 4881/4885 |
| US-20260034223-A1 | BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN | CALR, ERP44, PDIA4 | KDM4E 3192/4885SMN1; SMN2 2138/4885ALDH1A1 4750/4885 |
| US-12617818-B2 | Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them | MYLK2, TNNC1, MYOF | KDM4E 1287/4885SMN1; SMN2 51/4885ALDH1A1 4834/4885 |
| US-20260116948-A1 | T CELL RECEPTOR CONSTRUCTS AND USES THEREOF | MICA, IGSF11, IGLV6-57 | KDM4E 3464/4885SMN1; SMN2 2479/4885ALDH1A1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.